Philipp Rittershaus

VEROVACCiNES develops and markets a novel class of innovative, proprietary subunit marker vaccines for animal health. The technology provides a validated solution to the industry's need for - cost effective vaccines - reduce immunization effort - reduced use of antibiotics A recent development allows to combine several antigens (immunity generating substances) in an single vaccine without increasing production costs. This allows e.g. to target different pathogens with a single vaccine or to generate broad band vaccines targeting immunity evading variants of the same pathogen. The company has a pipeline of 5 vaccine programs at various developmental stages. Four of these programs have already been validated (proof of concept). Several candidates have blockbuster potential. We are developing vaccine solutions for poultry, swine and ruminants. VEROVACCiNES is engaged in collaborations with market leaders as well as with academic institutions.

RIMASYS GROUP is defined by the most innovative brands in medical technology to reinvent surgical education. With each brand, we are focusing on enhancing surgical education, and improving patient outcomes by deploying realistic fractures for practical skill training, medical device development and services. We are the novel approach to surgical education and MedTech R&D.

Volterion is the leading manufacturer of innovative redox-flow batteries and smart stacks for commercial bulk energy storage. We make the energy transition work. Our energy storage products are recyclable, safe and non-flammable. They are made in Germany for a long life-time and they have a low environmental impact compared with other storage technologies.

We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.

Newsenselab GmbH has developed M-sense Migraine. The application supports migraine sufferers in reducing their headaches and dealing with their condition in a self-determined manner. The innovative digital treatment program was developed together with leading headache specialists.

TolerogenixX vision is to innovate Immunosuppression with its newly developed MIC Cell Treatments. MIC Cell Treatment is a curative ATMP approach to achieve a sustained regulation of the immune system in Transplant - and Autoimmune Disease Patients. TolerogenixX has been able to generate strong pre-clinical as well as clinical data in the indications of Transplantation and Autoimmune Diseases e.g. SLE since its foundation in 2016.

At Heartbeat Medical, we believe that listening to the patients perspective will transform health care and empower everyone involved to make better decisions. We are focused on bringing the best technology and science to support all stakeholders in impacting what matters most to patients: their quality of life. Heartbeat Medical is one of the leading providers in Europe for the digital collection of health outcomes and deeply embedded in routine care in Germany and Switzerland. Acting as the driver of value-based healthcare in Germany, the company provides both technical infrastructure and organizational know-how to establish the standardized collection of clinical and patient-reported information. These efforts led to the successful implementation of patient-centered outcomes in over 350.000 treatments across a wide variety of medical areas. Find out more about our digital solutions and Patient Reported Outcome Measures at https://heartbeat-med.de

Moving from cell to blood based HPV cancer screening, Abviris has developed a new patented generation of Immune Oncology Diagnostics for the early detection of HPV induced cancer, allowing a blood based entire body screen within minutes by using just one drop of blood. Abviris addresses the globally increasing problem of cancer caused by the human papillomavirus (HPV). We are dedicated to improving the clinical outcomes of patients and enable clinicians worldwide to fight HPV-induced tumours, including head and neck cancer, penile and anal tumours, vaginal and vulvar cancer and of course cervical cancer. Our patented diagnostics provide a key contribution to a favourable prognosis, such as early tumour detection and enhanced post-therapy patient management. As pioneers in HPV serology, we develop highly innovative solutions, including the Prevo-Check®, the world´s first entire-body screening test for HPV16-induced cancer, which delivers results within minutes using just a single drop of blood.

AYOXXA - The translational proteomics company AYOXXA Biosystems GmbH, based in Cologne (Germany), is an international biotech company focused on the development of its proprietary beads-on-a-chip technology for advanced protein analysis. LUNARIS™. AYOXXA’s innovative multiplex protein analysis platform is a fully integrated system designed for the parallel analysis of multiple biomarkers in picogram amounts of biological samples, allowing scientists to gain a maximum of high quality and reproducible insights. LUNARIS™ is fully scalable, with integrated, image-based quality control and transparent data processing and management, enabling translational proteomics by addressing all the needs from basic to clinical research and development. AYOXXA is commercializing and expanding a portfolio of detection kits covering ophthalmology, model-to-man and immuno-oncology applications.

VEROVACCiNES develops and markets a novel class of innovative, proprietary subunit marker vaccines for animal health. The technology provides a validated solution to the industry's need for - cost effective vaccines - reduce immunization effort - reduced use of antibiotics A recent development allows to combine several antigens (immunity generating substances) in an single vaccine without increasing production costs. This allows e.g. to target different pathogens with a single vaccine or to generate broad band vaccines targeting immunity evading variants of the same pathogen. The company has a pipeline of 5 vaccine programs at various developmental stages. Four of these programs have already been validated (proof of concept). Several candidates have blockbuster potential. We are developing vaccine solutions for poultry, swine and ruminants. VEROVACCiNES is engaged in collaborations with market leaders as well as with academic institutions.

RIMASYS GROUP is defined by the most innovative brands in medical technology to reinvent surgical education. With each brand, we are focusing on enhancing surgical education, and improving patient outcomes by deploying realistic fractures for practical skill training, medical device development and services. We are the novel approach to surgical education and MedTech R&D.

Volterion is the leading manufacturer of innovative redox-flow batteries and smart stacks for commercial bulk energy storage. We make the energy transition work. Our energy storage products are recyclable, safe and non-flammable. They are made in Germany for a long life-time and they have a low environmental impact compared with other storage technologies.

We believe that in the near future peptides have found their way into new markets and are a well-known feed stock for better products in life sciences and beyond. NUMAFERM supports you in these developments – from discovery to commercial production.